Fortress Biotech, Inc.
FBIO
$1.63
-$0.015-0.92%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -29.21% | -5.57% | -13.27% | 5.24% | 21.93% |
| Total Other Revenue | -94.74% | -- | -- | -- | 42,122.22% |
| Total Revenue | -61.18% | -7.13% | -14.32% | 4.84% | 137.42% |
| Cost of Revenue | -25.40% | -44.99% | -51.86% | -31.12% | -61.89% |
| Gross Profit | -86.99% | 99.07% | 80.84% | 44.45% | 185.58% |
| SG&A Expenses | 41.93% | 1.20% | -14.80% | -29.20% | -42.10% |
| Depreciation & Amortization | -9.11% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.03% | -24.30% | -37.78% | -30.44% | -48.74% |
| Operating Income | -855.24% | 32.55% | 46.47% | 37.88% | 104.63% |
| Income Before Tax | 9.18% | -151.58% | 51.39% | 29.24% | 49.81% |
| Income Tax Expenses | -11.35% | -51.06% | -- | -- | -15.59% |
| Earnings from Continuing Operations | 9.21% | -148.92% | 51.39% | 29.24% | 49.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -0.79% | 143.48% | -48.22% | -29.76% | -35.39% |
| Net Income | 27.09% | -155.04% | 55.81% | 28.42% | 65.57% |
| EBIT | -855.24% | 32.55% | 46.47% | 37.88% | 104.63% |
| EBITDA | -583.07% | 33.04% | 47.09% | 37.89% | 107.08% |
| EPS Basic | 64.65% | 18.82% | 80.04% | 70.18% | 78.09% |
| Normalized Basic EPS | -86.05% | 96.25% | -60.12% | 63.82% | 252.75% |
| EPS Diluted | 64.65% | 18.82% | 80.04% | 70.18% | 78.09% |
| Normalized Diluted EPS | -86.05% | 96.25% | -60.12% | 63.82% | 252.75% |
| Average Basic Shares Outstanding | 141.96% | 162.68% | 148.29% | 152.52% | 77.95% |
| Average Diluted Shares Outstanding | 141.96% | 162.68% | 148.29% | 152.52% | 77.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 1.00% | 1.00% | -1.26% | -0.40% | -1.91% |